McKesson Corporation (MCK) Releases Earnings Results, Misses Expectations By $-0.70 EPS

McKesson Corporation (MCK) reported quarterly earnings results on Wednesday, May-4-2016. The company reported $2.44 earnings per share for the quarter, missing the analyst consensus estimate by $-0.70. Analysts had a consensus of $3.14. The company posted revenue of $46678.00 million in the period, compared to analysts expectations of $46810.61 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.

Many Wall Street Analysts have commented on McKesson Corporation. McKesson Corporation was Downgraded by Standpoint Research to ” Hold” on Apr 26, 2016. Avondale Initiated McKesson Corporation on Apr 19, 2016 to “Mkt Outperform”, Price Target of the shares are set at $203.McKesson Corporation was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016.

McKesson Corporation opened for trading at $167.8 and hit $168.85 on the upside on Monday, eventually ending the session at $168.43, with a gain of 0.36% or 0.61 points. The heightened volatility saw the trading volume jump to 15,54,718 shares. Company has a market cap of $38,501 M.

In a different news, on Apr 26, 2016, John H Hammergren (Chairman, President & CEO) sold 101,833 shares at $176.82 per share price. According to the SEC, on Mar 16, 2016, Nigel A Rees (SVP & Controller) sold 6,000 shares at $157.59 per share price. On Feb 3, 2016, Susan R Salka (director) purchased 1,000 shares at $156.21 per share price, according to the Form-4 filing with the securities and exchange commission.

McKesson Corporation (McKesson) is engaged in delivering pharmaceuticals medical supplies and healthcare information technology. The Company operates through two business segments: McKesson Distribution Solutions and Technology Solutions. The McKesson Distribution Solutions segment distributes drugs and equipment and health and beauty care products across North America and internationally. The Distribution Solutions segment provides pharmaceutical solutions for biotech and pharmaceutical manufacturers and practice management technology clinical support and business solutions to oncology and other specialty practices operating in the community setting. The Technology Solutions segment delivers clinical patient care financial supply chain and strategic management software solutions as well as connectivity outsourcing and other services including remote hosting and managed services to healthcare organizations.

McKesson Corporation

Leave a Reply

McKesson Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on McKesson Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.